[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].

Background: BCR-ABL negative myeloproliferative neoplasms (MPN) include polycythemia Vera (PV), essential thrombocythemia (ET) and primitive myelofibrosis (PMF). the JAK2 V617F mutation has been introduced since 2008 as a major diagnostic criterion on the one hand and on the other hand, it would be linked to increased risk of thrombotic complications.

Aim: This study aimed to evaluate the association of JAK2 mutation and thrombotic events in MPN.